Cardiovascular events and intensity of treatment in polycythemia vera

Autor: Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, Rm, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, M. L., Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, Ar, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, Am, Specchia G, Barbui T., D'Amico, A, Ferri, B, Guido, C, Marfisi, L, Pera, C, Polidoro, A, Sacco, M, Levantesi, G, Tognoni, G, Barosi, G, Carobbio, A, Leoni, P, Mulattieri, S, Tomassetti, S, Honorati, E, Ricco, A, Albano, F, Pastore, D, Carluccio, P, Mazzone, Am, Rossi, Ar, Finazzi, Mc, Delaini, F, Falanga, A, Rambaldi, A, Guaragna, G, Giannotta, A, Usala, E, Simula, Mp, Pilo, F, Cacciola, E, Pezzella, F, Seria, E, Di Francesco, E, Gallamini, A, Bertolotti, L, Antonioli, E, Guglielmelli, P, Pieri, L, Susini, Mc, Bartalucci, N, Bosi, A, D'Angelo, A, Centorrino, R, Gerace, D, Allegra, A, Cortelezzi, A, De Philippis, C, Ferretti, E, Ciceri, F, Claudiani, S, Malato, S, Trinca, S, Pogliani, Em, Belotti, A, Lanzi, E, Elli, Em, Gaidano, G, Deambrogi, C, Rossi, D, Saglio, G, Rotolo, A, Zanone, C, Bertozzi, I, Tezza, F, Aneloni, V, Quintini, G, Saccullo, G, Caracciolo, C, Cazzola, M, Casetti, I, Elena, C, Landini, B, Barulli, S, Guiducci, B, Lucesole, M, Malerba, L, Isidori, A, Grossi, A, De Stefanis, M, Biagioni, C, Merli, F, Imovilli, A, Codeluppi, K, Rubagotti, S, Romano, N, Bonini, A, Bellesia, E, Martorelli, Mc, Villani, O, Zifarone, E, Zonno, A, Santopietro, V, Za, T, Rossi, E, Ciminello, Am, Betti, S, Alimena, G, Tafuri, A, Breccia, M, Carmosino, I, Pisani, F, Romano, A, D'Andrea, M, Nobile, M, Mantuano, Fs, Rossi, G, Tricarico, M, Rodeghiero, F, Bedin, F, Lissandrini, L, Finotto, S.
Přispěvatelé: Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, RM, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, ML, Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, AR, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, AM, Barbui, T, CYTO-PV Collaborative Group.
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
Hematocrit
RECURRENT THROMBOSIS
law.invention
Aged
Antineoplastic Agents
Cardiovascular Diseases
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Hydroxyurea
Janus Kinase 2
Middle Aged
Polycythemia Vera
Thrombosis
Phlebotomy
Medicine (all)
LEUKOCYTOSIS
Polycythemia vera
Randomized controlled trial
law
hemic and lymphatic diseases
ESSENTIAL THROMBOCYTHEMIA
Clinical endpoint
Polycythemia Vera
Secondary Prophylaxis

ESSENTIAL THROMBOCYTHEMIA
RECURRENT THROMBOSIS
RISK-FACTOR
HEMATOCRIT
MANAGEMENT
LEUKOCYTOSIS
PREVENTION
DIAGNOSIS
EFFICACY
WARFARIN

medicine.diagnostic_test
Hazard ratio
General Medicine
medicine.medical_specialty
randomized trial
polycythemia vera
Cardiovascular event
DIAGNOSIS
WARFARIN
RISK-FACTOR
Internal medicine
MANAGEMENT
medicine
Myelofibrosis
Adverse effect
business.industry
EFFICACY
medicine.disease
PREVENTION
Surgery
Polycythemia Vera
Cardiovascular event
hematocrit

Settore MED/15 - MALATTIE DEL SANGUE
business
Popis: A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit
Databáze: OpenAIRE